UNSPSC 51123302: Asocainol hydrochloride

This classification denotes an antiarrhythmic agent with the molecular formula C27H31NO3.HCL, a preparation chemically known as 6,7,8,9-Tetrahydro-2,12-dimethoxy-7-methyl-6-phenethyl-5H-dibenz(d,f)azonin-1-ol hydrochloride but more generally known as asocainol hydrochloride. Most nations, for tariff and trade purposes, schedule asocainol hydrochloride under HS 29339990 and SITC 51577. SMILES: OC1C2C(CC(N(CCC3C2CC(OC)CC3)C)CCC2CCCCC2)CCC1OC.CL.

UNSPSC 51123302 Asocainol hydrochloride is a Commodity code used by state and local buyers for pharmaceutical procurement, though the recent opportunities block shows substantial activity in advanced life support medications and generic multi-source pharmaceuticals rather than asocainol specifically. State and local governments use this code tier to purchase medications for emergency medical services, pharmacy benefit programs, and health system operations. Issuing bodies include city fire rescue departments, state health and human services agencies, and multi-state cooperative purchasing alliances. The scope spans sealed bid procurements for individual medication line items with firm pricing and specific expiration-date warranties, state-level RFIs exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels, and cooperative RFPs for multi-state generic pharmaceutical distribution through authorized wholesalers with compliance requirements for cGMP, DSCSA, and FDA standards.

Recent activity concentrates in Florida and Texas, with broader multi-state reach through cooperative mechanisms. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications due April 8, 2026, requesting four medication line items totaling approximately 3,530 units with nine-month minimum expiration dates, firm pricing including shipping to Tampa, and a one-year contract term valued at $40,000.00 with SLBE sheltered-market designation. The Texas Health and Human Services Commission posted RFI HHS0017013 on March 27, 2026, with an April 3 response deadline, to explore vendor capacity for direct-to-manufacturer prescription programs supporting self-insured plans and state agencies outside traditional PBM and GPO relationships. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026, and performance penalties of $200 to $1,500 per violation for reporting or compliance failures.